News

SullivanCotter Insights Reveal Rising Trends in Physician Pay

SullivanCotter Insights Reveal Rising Trends in Physician Pay

SullivanCotter Report Highlights Increased Physician Compensation Trends

In a recent report by SullivanCotter, data reveals that physician compensation has rebounded to historical growth levels, with median total cash compensation (TCC) experiencing an annual increase of 3.5%. This growth follows a remarkable rise in 2023, where rising compensation became a significant topic.

Notable Growth Across Specialties

This year, two specialty categories, Adult Medical and Pediatric Surgery, recorded the highest increases in TCC at 4.5% and 4.4%, respectively. Over a five-year horizon, primary care physicians boasted a staggering compensation hike of 16.5% since 2020, reflecting changes in Medicare policies during this period. These adjustments, particularly the Medicare Physician Fee Schedule modifications made in 2021 and 2023, have prominently influenced physician earnings.

Data Collection Overview

SullivanCotter’s report stands as one of the most extensive compilations of physician compensation data available. This year, the survey comprised data from over 500 hospitals and health systems, encompassing nearly 215,000 physicians across 212 specialties. The survey's comprehensive nature signifies a 13% increase in the reported physician records compared to the previous year.

Shifts in Workforce Expectations

In 2024, several market dynamics are impacting physician compensation trends. Particularly, the most profound shift has been in physicians' workforce expectations influenced by the COVID-19 pandemic. This evolving landscape has led to a substantial demand for improved work-life balance, with many physicians seeking reduced call hours, more paid time off, and a stable compensation structure.

Insights from Leadership

“The pandemic exacerbated workforce expectations for a more sustainable work life. We’re observing reduced call expectations, additional paid time off, and more appealing fixed compensation structures,” stated Dave Hesselink, Managing Principal at SullivanCotter. Notably, the 2024 survey noted decreases in expected annual work hours particularly in Critical Care, Hospital Medicine, and Radiology.

Driving Factors Behind Compensation Increases

The growth in TCC reported in this year’s survey has primarily resulted from increased productivity among physicians. The report showcases a 4-6% bump in median work relative value unit (wRVU) productivity for specialties including Adult Medical, Primary Care, and Pediatric Medicine, aligning this trend with recovery patterns post-pandemic.

Hospital-Based Specialties and wRVU Increases

Particularly in hospital-based specialties, such as Hospitalist – Family Medicine, Emergency Medicine, and Hospitalist – Internal Medicine, wRVU values increased by 9.1%, 8.6%, and 8.3% respectively, signaling a positive trend in compensation based on productivity.

Compensation Structure in 2024

The findings also emphasize the prevalence of base salary and wRVU productivity as core elements of compensation plans in Primary Care, Medical, and Surgical specialties. These components are reported to constitute about 65-75% of compensation structures, reflecting stability in trends compared to last year. Moreover, about 50% of organizations are implementing value-based incentives averaging 6.8% of TCC for specialists and 8.6% for Primary Care providers.

Conclusion: A Move Toward Tailored Compensation

While overarching compensation design strategies remain largely unchanged, the report indicates a move away from uniform compensation plans. As healthcare aligns more with value-based care delivery models, variations in compensation will become evident across specialties. Mark Ryberg, Physician Workforce Practice Leader at SullivanCotter, notes, “The era of a ‘one-size-fits-all’ compensation model is over as health systems adapt to distinct care delivery needs.”

About SullivanCotter

SullivanCotter is dedicated to helping healthcare and non-profit organizations enhance performance and achieve better outcomes through tailored workforce strategies. They provide crucial, data-driven insights to align business objectives with performance measures, supporting clients in fulfilling their missions and values.

Frequently Asked Questions

What does the SullivanCotter report reveal about physician compensation?

The report indicates a return to historical growth levels in physician compensation, with a median total cash compensation increase of 3.5% across specialties.

Which specialties saw the largest compensation increases?

The Adult Medical and Pediatric Surgical categories recorded the largest increases in total cash compensation at 4.5% and 4.4%, respectively.

How has the workforce's expectations changed post-pandemic?

Physicians now prioritize work-life balance, leading to demands for fewer call hours, increased paid time off, and more stable compensation structures.

What role does wRVU productivity play in compensation?

Increases in total cash compensation are significantly driven by productivity; wRVU metrics show an upsurge across various specialties.

What is the outlook for compensation structure in 2024?

The report suggests a shift towards customized compensation models that mitigate the ‘one-size-fits-all’ approach, reflecting varying needs of physicians based on their specialties.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 104

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 163

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 98

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 339

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 176

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 71

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading